Neshima Medical

Company Overview

Snapshot

Founded in April 2020 by Yan Ostrovski, Ramy Fishler, Avital Frenkel, and Josué Sznitman, Neshima Medical operates with 1–10 employees. The company has raised $250,000 across two funding rounds from three investors.

Business overview

Neshima Medical is a health tech and life sciences company developing life-saving treatments for severe lung diseases. The company's core technology is LiFT™, a patented foam-based delivery platform designed to enable deep and uniform therapeutic delivery to the alveoli, addressing limitations of traditional treatment methods. Neshima Medical's lead applications include a regenerative cell therapy for COPD and an ICU-delivered antibiotic treatment for antimicrobial-resistant infections. The company targets a $10 billion U.S. market with a B2B model, operating within the Pharma & Medical Biotechnology and Drug Delivery sectors.

Strategic signal

This investment signals continued investor confidence in Neshima Medical's innovative LiFT™ foam-based delivery platform and its potential to address critical needs in respiratory disease treatment, reinforcing the company's strategic trajectory in the health tech and life sciences sector.

Company Intelligence Q&A

When was Neshima Medical founded and by whom?

Neshima Medical was founded in April 2020 by Yan Ostrovski, Ramy Fishler, Avital Frenkel, and Josué Sznitman.

What is Neshima Medical's primary technology?

Neshima Medical's primary technology is LiFT™, a patented foam-based delivery platform designed for deep and uniform therapeutic delivery to the alveoli for severe lung diseases.

What markets does Neshima Medical target?

Neshima Medical targets the U.S. market with a B2B model, focusing on Europe, Israel, and North America for its geomarkets.